Geospace Technologies Corporation Reports Profitable Third Quarter and Nine-Month 2025 Earnings
HOUSTON–(BUSINESS WIRE)–#energyexploration–Geospace Technologies Corporation (NASDAQ: GEOS) (“the “Company”) today announced results... Read more.
Ellington Financial Inc. Reports Second Quarter 2025 Results
OLD GREENWICH, Conn.–(BUSINESS WIRE)–Ellington Financial Inc. (NYSE: EFC) (“we”) today reported financial results for the quarter ended June... Read more.
nLIGHT, Inc. Compensation Committee Announces Intent to Grant Special Equity Awards
CAMAS, Wash.–(BUSINESS WIRE)–nLIGHT, Inc. (Nasdaq: LASR), a leading provider of high-power lasers for mission critical directed energy, optical sensing,... Read more.
Forum Energy Technologies Announces Second Quarter 2025 Results; Raises Full Year 2025 Cash Flow Guidance
Orders: $263 million; 132% book-to-bill ratio; highest backlog in more than ten years Revenue: $200 million, up 3% sequentially Net income: $8 million, or $0.61... Read more.
NGL Energy Partners LP Announces First Quarter Fiscal 2026 Financial Results
TULSA, Okla.–(BUSINESS WIRE)–NGL Energy Partners LP (NYSE:NGL) (“NGL,” “we,” “us,” “our,” or the “Partnership”) today reported its... Read more.
C.H. Robinson Declares Quarterly Cash Dividend
EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–$CHRW #CHRobinson–C.H. Robinson Worldwide, Inc. (“C.H. Robinson”) (Nasdaq: CHRW) announced that its Board... Read more.
indie Semiconductor Reports Second Quarter 2025 Results
Delivers second quarter revenue of $51.6 million with Non-GAAP Gross Margin of 49.1 percent, both above the midpoint of the outlook Continued design win momentum... Read more.
C.H. Robinson Declares Quarterly Cash Dividend
EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–$CHRW #CHRobinson–C.H. Robinson Worldwide, Inc. (“C.H. Robinson”) (Nasdaq: CHRW) announced that its Board... Read more.
Stone Ridge Buys Oklahoma Assets From ConocoPhillips
Acquisition Brings Stone Ridge Energy’s Portfolio to Over 11 GW of Power NEW YORK–(BUSINESS WIRE)–Stone Ridge Holdings Group (“Stone Ridge”), a... Read more.
Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update
Topline results of PALISADE-3 Phase 3 Trial of fasedienol for acute treatment of social anxiety disorder expected in the fourth quarter of 2025 PALISADE-4 Phase... Read more.